Keyphrases
Adverse Effects
16%
Antibody Adsorption
33%
Aseptic Technique
16%
Benzyl Isothiocyanate
16%
Cancer Patients
16%
Clinical Dose
50%
Clinical Setting
16%
Clinical Trials
33%
Cyclotron
16%
Desferrioxamine
16%
Human Epidermal Growth Factor Receptor 2 (HER2)
16%
Incubation Period
33%
Labeled Antibody
33%
Labeling Efficiency
16%
Low Specific Activity
16%
Microfluidic Reactor
50%
Microfluidics
100%
Microreactor
16%
Molar Ratio
16%
Monoclonal Antibody
16%
Nuclear Imaging
16%
Nuclear Molecular Imaging
16%
Octadecyl
16%
Optimal Labeling
16%
Oxalate
16%
Patient Dose
100%
Patient Throughput
16%
Polydimethylsiloxane
16%
Quality Control Guidelines
16%
Radiochemical Purity
16%
Radiolabeled Antibody
33%
Radiopharmaceuticals
16%
Reactor
33%
Silane
16%
Single Patient
100%
Specific Activity
50%
Time Requirement
16%
Trastuzumab
100%
Trimethoxy
16%
Zirconium-89 (89Zr)
100%
Pharmacology, Toxicology and Pharmaceutical Science
Benzyl Isothiocyanate
16%
Clinical Trial
33%
Deferoxamine
16%
Dimeticone
16%
Epidermal Growth Factor Receptor 2
16%
Gamma Urogastrone
16%
Incubation Time
33%
Malignant Neoplasm
16%
Monoclonal Antibody
16%
Receptor
16%
Side Effect
16%
Trastuzumab
100%
Trimethoxyoctadecylsilane
16%
Zirconium 89
100%